NASDAQ: EIGR

Eiger BioPharmaceuticals, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2023.

If you purchased Eiger securities during the Class Period and would like to join the action, please click “Join This Class Action.”

集体诉讼期:March 10, 2021 through October 4, 2022
If you purchased Eiger securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

案件详情:

According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:

  • defendants overstated Eiger’s clinical and regulatory drug development expertise;
  • defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the peginterferon lambda Emergency Use Authorization (“EUA”);
  • there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic;
  • as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA;
  • as a result of all the foregoing, peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated; and
  • as a result, Eiger’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

关注我们:
公司名称: Eiger BioPharmaceuticals, Inc.
股票代号: EIGR
集体诉讼期: March 10, 2021 through October 4, 2022
法院: United States District Court for the Northern District of California

为何选择罗森律师事务所?

自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。

投资者应仔细鉴别和遴选在引领证券集体诉讼方面有多年成功经验的的律师。通常,其他律所会发布关于集体诉讼的新闻稿,但却没有类似的经验或资源。

机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。

罗森律师事务所为全球投资者提供代理服务。我们的使命是提起证券欺诈集体诉讼以及保护股东的权利。

滚动至顶部